Lauxera Capital Partners
Paris-based healthcare growth-equity firm founded January 2020 specializing in European medtech, biotech and HealthTech scale-ups; deploys EUR 780M across Lauxera Growth I (vintage 2022 EUR 260M) and Lauxera Growth II (vintage 2025 EUR 520M oversubscribed hard cap of EUR 500M) with offices in Paris (41 Avenue de Friedland) and San Francisco (Mill Valley CA); notable exit OrganOx to Terumo USD 1.5bn October 2025.
Key facts
Recent exits
Coverage notes
2 funds tracked, 14 portfolio companies (13 active · 1 realized). Verified weekly from public filings and deal announcements.
Funds & portfolio
Every fund Lauxera Capital Partners has raised, with its portfolio companies. Hand-checked from public filings.
Lauxera Growth IIGrowth2025 · 1yr€520M2 active
Unrealized
2 held| Company | Sector | Geo | Entry |
|---|---|---|---|
| Acandis | Healthcare | Germany | 2024 |
| Antaros Medical | Healthcare | Sweden | 2025 |
Lauxera Growth IGrowth2022 · 4yr€260M11 active · 1 realized
Unrealized
11 held| Company | Sector | Geo | Entry |
|---|---|---|---|
| BioLamina | Healthcare | Sweden | 2023 |
| Caresyntax | Healthcare | Germany | 2023 |
| Lifen | Healthcare | France | 2018 |
| LUMICKS | Healthcare | Netherlands | 2022 |
| Matrix One | Healthcare | Germany | 2023 |
| Natural Cycles | Healthcare | Sweden | 2024 |
| Ospi | Healthcare | France | 2024 |
| Reapplix | Healthcare | Denmark | 2023 |
| Synovo Group | Healthcare | France | 2023 |
| Veranex | Healthcare | United States | 2022 |
| Verdot | Healthcare | France | 2022 |
Saved GPs appear in your watchlist, one click from your workspace.
About Lauxera Capital Partners
Lauxera Capital Partners is a Paris-based healthcare growth equity firm with €660 million of assets under management as of December 2024, founded in January 2020. The firm specialises in European medtech, biotech and HealthTech scale-ups, deploying capital across Lauxera Growth I (vintage 2022, €260M) and Lauxera Growth II (vintage 2025, €400M) with selective offshore exposure to North American healthcare opportunities.
Investment thesis
Lauxera targets European healthcare growth equity in profitable medtech, biotech and HealthTech scale-ups, with equity tickets typically ranging from €20 million to €60 million per transaction. The growth equity mandate enables Lauxera to back profitable healthcare businesses seeking expansion capital rather than early-stage venture exposure, with the healthcare-exclusive focus providing clinical and regulatory expertise across portfolio companies.
Recent activity
Recent realised exits include OrganOx (healthcare, 2025), reflecting selective distribution activity across the healthcare growth portfolio. The platform tracks 2 funds and 13 active portfolio companies across the healthcare-exclusive programme. Detailed buyer names and multiple data available on Pro at €29/month.
Similar firms
Other private equity firms tracked on GP Intel.
France·€196.0BFrance·€52.8BFrance·€33.0BFrance·€27.0BFrance·€13.2BFrance·€11.6BFrance·€9.0BFrance·€7.0BFrance·€6.7BFrance·€4.3BFrance·€4.0BFrance·€4.0B